Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Streetinsider.com's Hot Lunchtime Reads 9/25: (MU) (ACOR) (ADNC) (AAPL)
-
Chardan Cuts PT on Audience (ADNC) to $8; iPhone 6 Success May Equal Lower Sales for Key Customer
-
Chardan Capital Remains Positive on Endocyte (ECYT) into 2014 ESMO Congress
-
Chardan Capital Markets Starts Abtech Holdings (ABHD) at Buy
-
22nd Century Group (XXII) Closes 3.87M Common Private Placement
-
Medivation (MDVN) PT Lifted to $122 at Chardan Capital Markets
-
Streetinsider.com's Hot Lunchtime Reads 9/9: (HD) (MBLY) (CRM) (EL)
-
Chardan Lowers PT on MaxLinear (MXL) to $7.50 Following Updated Q3 Guidance
-
Chardan Positive on Strong Sales Price for iPass (IPAS); Affirms 'Buy' Rating
-
Ambarella (AMBA) PT Raised to $35 at Chardan Capital Markets; 'Neutral' Maintained
-
Chardan Sees China Mobile Subs Growth, Cut Subsidies Adding to Himax (HIMX) Weakness in H214
-
CHardan Remains Positive, Comments on Profire (PFIE) Following Q1 Results
-
Chardan Capital Markets Starts Medical Transcription Billing (MTBC) at Buy
-
Globalstar (GSAT) Buy Rating Reiterated at Chardan Capital (Earlier)
-
MTBC to Release Q2 2014 Financial Results on August 27, 2014
-
Streetinsider.com's Hot Lunchtime Reads 08/07: (TWX) (HIMX) (SRPT) (AAPL)
-
Himax (HIMX) Q2 Results, Q3 Guidance Were Solid, but Google Glass Remains 2015 Event - Chardan Capital
-
Notable Analyst Rating Changes 08/07: (AOL) (CAT) (CCL) Upgraded; (AET) (XXIA) (NUS) Downgraded
-
Chardan Affirms ARIAD (ARIA) at 'Buy'; Narrower Label Impacts Iclusig Usage
-
Chardan Capital Markets Starts MOKO Social Media (MOKO) at Buy
-
Margin Pressure Could Clip Himax's (HIMX) Q2 Profit and Hamper Outlook - Chardan Capital
-
Chardan Capital Markets Downgrades Audience, Inc. (ADNC) to Neutral
-
Chardan Capital Affirms Endocyte (ECYT) at Buy Following Q2 Results, Operational Update
-
MTBC Announces Concurrent Closings of Initial Public Offering on NASDAQ and Three Strategic Asset Purchases
-
La Jolla Pharma (LJPC) Poised to Open Lower After 5.4M Offering Prices at $10.50/Share
-
La Jolla Pharmaceutical (LJPC) Prices 4.8M Common Offering at $10.50/Share
-
Chardan Cuts PT on Himax (HIMX) to $4.50; Weak Q3 Guidance Expected; Google Mum on Glass
-
MTBC Announces Pricing of Initial Public Offering
-
Nuvilex Provides Shareholder Update on Milestone Accomplishments
-
PlacementTracker Publishes First Half 2014 PIPE Market League Tables
-
Streetinsider.com's Hot Lunchtime Reads 07/08: (PETM) (AAPL) (CNCE) (MSFT)
-
Chardan Capital Lowers Ests on Profire Energy (PFIE) Following Equity Offering, Q4 Results
-
Chardan Capital Sees KVH Industries' (KVHI) Acquisition of Videotel as 'Significant'; Boosts Ests
-
Chardan Positive on StemCells (STEM) Following Interview with Dr. Armin Curt; Reaffirms 'Buy' Rating
-
MOKO Social Media (MOKO) IPO Opens Higher, Drifts Lower
-
Profire Energy (PFIE) Prices 6M Offering at $4/Share
-
Streetinsider.com's Hot Lunchtime Reads 06/25: (MON) (SHPG) (ADPT) (ADNC)
-
Chardan Capital Positive on Audience's (ADNC) Move to Acquire Sensor Platforms; Affirms at 'Buy'
-
Himax Technologies (HIMX) Q2 Numbers at Risk - Chardan Capital Markets
-
StemCells (STEM) Interim Phase 1/2 dry AMD Data Exceeded Expectations; Chardan Capital Keeps at 'Buy'
-
Chardan Capital Cuts PT on Endocyte (ECYT) to $15 After Regaining Vintafolide Rights
-
Chardan Positive on StemCells (STEM) into Presentation of HuCNS-SC Phase I/II Dry AMD at ISSCR
-
Chardan Capital Markets Downgrades CEVA Inc. (CEVA) to Sell
-
Himax (HIMX) Sell-Off Related to Speculation Synaptics to Acquire Renesas Display Driver Business - Chardan Capital Markets
-
LiveDeal Inc. (LIVE) Comments on 10M ATM Filing
-
Chardan Capital Market Reiterates Bullish Stance on YOU On Demand (YOD) on 'Impressive' FY14 Guidance
-
Chardan Capital Markets Upgrades The KEYW Holding Corporation (KEYW) to Buy
-
Chardan Capital Markets Starts Immune Pharmaceuticals (IMNP) at Buy, $11 PT
-
Chardan Capital Markets Downgrades Acorn Energy (ACFN) to Neutral
-
UPDATE: Chardan Capital Markets Downgrades Himax Technologies (HIMX) to Sell

